Ligand source activities (1 row/activity)



Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Potency)		 # tested GPCRs
(Potency)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
CHEMBL3102930 217817 0 None - 1 Human 10.3 pEC50 = 10.3 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O 10.1021/ml400257h
168299476 199525 0 None -1 3 Human 10.2 pEC50 = 10.2 Functional
Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
ChEMBL 4660 165 74 67 -19.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O 10.1021/acs.jmedchem.0c01396
CHEMBL5220770 199525 0 None -1 3 Human 10.2 pEC50 = 10.2 Functional
Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
ChEMBL 4660 165 74 67 -19.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O 10.1021/acs.jmedchem.0c01396
CHEMBL4294827 220311 0 None 2 2 Human 10.1 pEC50 = 10.1 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NC(CC(N)=O)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O nan
CHEMBL1893324 215839 24 None -1 3 Human 10.1 pEC50 = 10.1 Functional
Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1021/acs.jmedchem.0c01396
2263 7045 0 None -1 3 Human 10.1 pEC50 = 10.1 Functional
Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation
ChEMBL None None None None 10.1021/jm0609059
44566111 7045 0 None -1 3 Human 10.1 pEC50 = 10.1 Functional
Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation
ChEMBL None None None None 10.1021/jm0609059
CHEMBL219499 7045 0 None -1 3 Human 10.1 pEC50 = 10.1 Functional
Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation
ChEMBL None None None None 10.1021/jm0609059
CHEMBL3102924 217811 0 None - 1 Human 10.0 pEC50 = 10 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O 10.1021/ml400257h
CHEMBL3102925 217812 0 None - 1 Human 10.0 pEC50 = 10.0 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C 10.1021/ml400257h
CHEMBL3102919 217806 0 None - 1 Human 9.9 pEC50 = 9.9 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL4277441 220150 0 None 1202 2 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
1152 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
16129679 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
16132300 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
53395115 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
91898389 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL1981592 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
nan 10767 16 None -3 8 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL3102922 217809 0 None - 1 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL3102929 217816 0 None - 1 Human 9.7 pEC50 = 9.7 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None C=CCCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O 10.1021/ml400257h
CHEMBL3102931 217818 0 None - 1 Human 9.5 pEC50 = 9.5 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O 10.1021/ml400257h
CHEMBL3102921 217808 0 None - 1 Human 9.4 pEC50 = 9.4 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL3105020 217850 0 None - 1 Human 9.4 pEC50 = 9.4 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC1=O)C(C)C 10.1021/ml400257h
CHEMBL4291119 220285 0 None 22 2 Human 9.4 pEC50 = 9.4 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCCN)CC(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4277799 220159 0 None 977 2 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4285873 220238 0 None - 1 Human 9.2 pEC50 = 9.2 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL440082 220639 0 None - 1 Human 9.2 pEC50 = 9.2 Functional
Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O 10.1021/jm0609059
CHEMBL4282016 220207 0 None 204 2 Human 9.2 pEC50 = 9.2 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O nan
CHEMBL4281547 220200 0 None - 1 Human 9.1 pEC50 = 9.1 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4277870 220160 0 None 1659 2 Human 9.1 pEC50 = 9.1 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4294951 220313 0 None - 1 Human 9.0 pEC50 = 9.0 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4289726 220266 0 None - 1 Human 9.0 pEC50 = 9.0 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O nan
CHEMBL3102923 217810 0 None - 1 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O 10.1021/ml400257h
CHEMBL4291903 220290 0 None 660 2 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O nan
CHEMBL4276843 220146 0 None - 1 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4286419 220242 0 None 234 2 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4282364 220210 0 None 1071 2 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NC(CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL3102926 217813 0 None - 1 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C 10.1021/ml400257h
CHEMBL4283432 220219 0 None - 1 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCNC(=N)N)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL3102927 217814 0 None - 1 Human 8.8 pEC50 = 8.8 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C 10.1021/ml400257h
CHEMBL3105019 217849 0 None - 1 Human 8.8 pEC50 = 8.8 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C 10.1021/ml400257h
CHEMBL4294843 220312 0 None -11 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)NC(CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4281814 220203 0 None -58 2 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4284858 220228 0 None - 1 Human 8.5 pEC50 = 8.5 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL4287451 220248 0 None 426 2 Human 8.5 pEC50 = 8.5 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NC(CCC(N)=O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C nan
CHEMBL3102928 217815 0 None - 1 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None C=CCCC[C@](C)(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC 10.1021/ml400257h
CHEMBL4280273 220184 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4277709 220156 0 None -870 2 Human 5.3 pEC50 = 5.3 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4278228 220167 0 None - 1 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O nan
CHEMBL4281905 220205 0 None 1 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4285866 220237 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL3102920 217807 0 None - 1 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
ChEMBL None None None None 10.1021/ml400257h
CHEMBL4277783 220158 0 None 1 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CC(CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4284839 220227 0 None -11 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4280734 220188 0 None -223 2 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
CHEMBL4284961 220230 0 None 9 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CC(Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O nan
CHEMBL4278811 220171 0 None - 1 Human 6.0 pEC50 = 6 Functional
Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C nan
11570626 9328 46 None -794 9 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl 10.1021/jm300579z
9135 9328 46 None -794 9 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl 10.1021/jm300579z
CHEMBL1933349 9328 46 None -794 9 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl 10.1021/jm300579z
DB12044 9328 46 None -794 9 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl 10.1021/jm300579z
60170971 88176 0 None -186 3 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
CHEMBL2159348 88176 0 None -186 3 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
60170970 88175 0 None -281 4 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
CHEMBL2159347 88175 0 None -281 4 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 587 9 2 5 7.5 COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
60171059 88177 0 None -794 4 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 621 9 2 5 7.9 COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
CHEMBL2159349 88177 0 None -794 4 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter
ChEMBL 621 9 2 5 7.9 COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1 10.1021/jm300579z
90154832 159898 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
CHEMBL3976408 159898 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
168298339 199488 0 None -1 3 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
ChEMBL 4137 147 67 59 -16.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C 10.1021/acs.jmedchem.0c01396
CHEMBL5219662 199488 0 None -1 3 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
ChEMBL 4137 147 67 59 -16.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C 10.1021/acs.jmedchem.0c01396
1152 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
16129679 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
16132300 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
53395115 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
91898389 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
CHEMBL1981592 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
nan 10767 16 None -3 8 Human 7.3 pEC50 = 7.3 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
16133238 9764 0 None -85 6 Human 7.6 pEC50 = 7.6 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2257 9764 0 None -85 6 Human 7.6 pEC50 = 7.6 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
44134520 9764 0 None -85 6 Human 7.6 pEC50 = 7.6 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2258 9765 0 None -17 4 Human 7.7 pEC50 = 7.7 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
1152 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
16129679 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
16132300 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
53395115 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
91898389 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
CHEMBL1981592 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
nan 10767 16 None -3 8 Human 7.8 pEC50 = 7.8 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
2272 9852 0 None 14 3 Human 8.3 pEC50 = 8.3 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2259 10119 0 None 190 4 Human 8.3 pEC50 = 8.3 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 10570056
1152 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
16129679 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
16132300 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
53395115 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
91898389 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
CHEMBL1981592 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
nan 10767 16 None -3 8 Human 9.2 pEC50 = 9.2 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2258 9765 0 None -17 4 Human 9.3 pEC50 = 9.3 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
129887154 7370 0 None 177 3 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 11978642
155817438 7370 0 None 177 3 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 11978642
16214732 7370 0 None 177 3 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 11978642
2269 7370 0 None 177 3 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 11978642
2281 7370 0 None 177 3 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 11978642
16133238 9764 0 None -85 6 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2257 9764 0 None -85 6 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
44134520 9764 0 None -85 6 Human 9.4 pEC50 = 9.4 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2272 9852 0 None 14 3 Human 8.4 pEC50 = 8.4 Functional
inhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptorinhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2278 7116 0 None -4168 3 Human 5.9 pEC50 = 5.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
1152 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
16129679 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
16132300 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
53395115 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
91898389 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
CHEMBL1981592 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
nan 10767 16 None -3 8 Human 7.9 pEC50 = 7.9 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
16133238 9764 0 None -85 6 Human 8.4 pEC50 = 8.4 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2257 9764 0 None -85 6 Human 8.4 pEC50 = 8.4 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
44134520 9764 0 None -85 6 Human 8.4 pEC50 = 8.4 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2276 10118 0 None 316 2 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
1152 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
16129679 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
16132300 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
53395115 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
91898389 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
CHEMBL1981592 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
nan 10767 16 None -3 8 Human 8.5 pEC50 = 8.5 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2259 10119 0 None 190 4 Human 8.7 pEC50 = 8.7 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
1152 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
16129679 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
16132300 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
53395115 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
91898389 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
CHEMBL1981592 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
nan 10767 16 None -3 8 Human 9.3 pEC50 = 9.3 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
2278 7116 0 None -4168 3 Human 5.0 pEC50 > 5 Functional
calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
2278 7116 0 None -4168 3 Human 5.0 pEC50 > 5 Functional
cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633
3842 9214 0 None -1584 5 Human 6.0 pEC50 > 6 Functional
stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2272 9852 0 None 14 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptorinhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptor
Guide to Pharmacology None None None None 16930633


Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Affinity)		 # tested GPCRs
(Affinity)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
CHEMBL524852 222400 6 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
118334911 151094 0 None - 0 Human 5.0 pIC50 = 5 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 534 10 4 5 2.8 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2 nan
CHEMBL3905363 151094 0 None - 0 Human 5.0 pIC50 = 5 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 534 10 4 5 2.8 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2 nan
73890927 155674 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 524 11 4 6 2.4 COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3941654 155674 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 524 11 4 6 2.4 COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334840 155309 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 522 11 4 5 2.9 CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3938565 155309 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 522 11 4 5 2.9 CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334843 156031 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 508 10 4 5 2.7 Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3944350 156031 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 508 10 4 5 2.7 Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
2263 7045 0 None - 1 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells
ChEMBL None None None None 10.1021/jm0609059
44566111 7045 0 None - 1 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells
ChEMBL None None None None 10.1021/jm0609059
CHEMBL219499 7045 0 None - 1 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells
ChEMBL None None None None 10.1021/jm0609059
90154832 159898 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
CHEMBL3976408 159898 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
118334841 160300 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 519 10 4 6 2.2 N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3979900 160300 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 519 10 4 6 2.2 N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334918 155631 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 522 10 4 5 3.0 Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C nan
CHEMBL3941270 155631 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 522 10 4 5 3.0 Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C nan
118334912 161101 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 572 11 4 7 1.8 CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3986723 161101 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 572 11 4 7 1.8 CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334831 153894 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 552 10 4 7 2.1 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2 nan
CHEMBL3927475 153894 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 552 10 4 7 2.1 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2 nan
CHEMBL507480 221114 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
90154832 159898 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
CHEMBL3976408 159898 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay
ChEMBL 539 11 4 7 2.3 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1 nan
118334842 160631 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 562 10 4 5 3.4 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1 nan
CHEMBL3982797 160631 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 562 10 4 5 3.4 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1 nan
CHEMBL440082 220639 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells
ChEMBL None None None CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O 10.1021/jm0609059
118334830 161024 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 528 10 4 5 3.0 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1 nan
CHEMBL3986225 161024 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 528 10 4 5 3.0 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1 nan
118334834 159090 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 11 4 5 3.5 CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3969613 159090 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 11 4 5 3.5 CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
127035881 143263 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3264 105 48 45 -10.6 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
CHEMBL3736134 143263 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3264 105 48 45 -10.6 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
127035881 143263 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3264 105 48 45 -10.6 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
CHEMBL3736134 143263 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3264 105 48 45 -10.6 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
90154607 160583 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 538 10 4 7 2.1 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2 nan
CHEMBL3982346 160583 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 538 10 4 7 2.1 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2 nan
118334924 153915 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 542 11 3 5 3.7 CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1 nan
CHEMBL3927669 153915 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 542 11 3 5 3.7 CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1 nan
118334910 151426 0 None - 0 Human 4.4 pIC50 = 4.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 538 11 5 6 2.4 CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3908152 151426 0 None - 0 Human 4.4 pIC50 = 4.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 538 11 5 6 2.4 CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334914 158138 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 12 4 5 3.3 CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3961248 158138 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 12 4 5 3.3 CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334919 160314 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 552 13 4 6 3.1 CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3980013 160314 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 552 13 4 6 3.1 CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
73890939 159610 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 11 4 6 2.6 CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3973956 159610 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 536 11 4 6 2.6 CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334917 157982 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 566 13 4 6 3.5 CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
CHEMBL3959870 157982 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 566 13 4 6 3.5 CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1 nan
118334925 149167 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 550 12 3 6 3.2 CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1 nan
CHEMBL3889643 149167 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 550 12 3 6 3.2 CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1 nan
127034614 143281 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3246 105 48 45 -10.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
CHEMBL3736230 143281 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3246 105 48 45 -10.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
127034614 143281 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3246 105 48 45 -10.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
CHEMBL3736230 143281 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis
ChEMBL 3246 105 48 45 -10.8 CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O 10.1016/j.ejmech.2015.09.017
118334931 149220 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 566 11 3 7 2.8 CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2 nan
CHEMBL3890096 149220 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 566 11 3 7 2.8 CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2 nan
118334909 156191 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 512 10 4 5 2.5 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1 nan
CHEMBL3945729 156191 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay
ChEMBL 512 10 4 5 2.5 O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1 nan
3842 9214 0 None - 0 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
1155 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16129665 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
3643 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
CHEMBL1201488 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
DB00021 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
3293 7256 0 None - 0 Rat 5.0 pIC50 = 5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
3293 7256 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
1155 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16129665 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
3643 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
CHEMBL1201488 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
DB00021 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
1152 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16129679 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16132300 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
53395115 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
91898389 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
CHEMBL1981592 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
nan 10767 16 None -5 4 Human 8.3 pIC50 = 8.3 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
1152 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16129679 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
16132300 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
53395115 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
91898389 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
CHEMBL1981592 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
nan 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
129887154 7370 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
155817438 7370 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
16214732 7370 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
2269 7370 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
2281 7370 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
16133238 9764 0 None - 3 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
2257 9764 0 None - 3 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
44134520 9764 0 None - 3 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
131850923 9851 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
155817437 9851 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
16154651 9851 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
2268 9851 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
131850923 9851 0 None - 0 Rat 5.7 pIC50 = 5.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
155817437 9851 0 None - 0 Rat 5.7 pIC50 = 5.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
16154651 9851 0 None - 0 Rat 5.7 pIC50 = 5.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
2268 9851 0 None - 0 Rat 5.7 pIC50 = 5.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9437716
2266 9669 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
16133238 9764 0 None - 3 Human 7.6 pIC50 = 7.6 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2257 9764 0 None - 3 Human 7.6 pIC50 = 7.6 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
44134520 9764 0 None - 3 Human 7.6 pIC50 = 7.6 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
1152 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
16129679 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
16132300 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
53395115 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
91898389 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
CHEMBL1981592 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
nan 10767 16 None -5 4 Human 7.7 pIC50 = 7.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2259 10119 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
2259 10119 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
2259 10119 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9145428
1155 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16129665 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
3643 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
CHEMBL1201488 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
DB00021 10345 0 None - 2 Rat 4.5 pIC50 = 4.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
1155 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16129665 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
3643 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
CHEMBL1201488 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
DB00021 10345 0 None - 2 Human 5.3 pIC50 = 5.3 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
131850923 9851 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
155817437 9851 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
16154651 9851 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
2268 9851 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
2273 9883 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2273 9883 0 None - 0 Rat 7.5 pIC50 = 7.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16133238 9764 0 None - 3 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16133238 9764 0 None - 3 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2257 9764 0 None - 3 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2257 9764 0 None - 3 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
44134520 9764 0 None - 3 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
44134520 9764 0 None - 3 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2275 9888 0 None - 0 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
1152 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
1152 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
16129679 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
16129679 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
16132300 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
16132300 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
53395115 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
53395115 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
91898389 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
91898389 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
CHEMBL1981592 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
CHEMBL1981592 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
nan 10767 16 None -5 4 Human 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
nan 10767 16 None - 4 Rat 8.0 pIC50 = 8 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
2275 9888 0 None - 0 Rat 8.2 pIC50 = 8.2 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
1152 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16129679 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16132300 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
53395115 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
91898389 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
CHEMBL1981592 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
nan 10767 16 None - 4 Rat 8.4 pIC50 = 8.4 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16132369 8699 0 None - 1 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16132369 8699 0 None - 1 Rat 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2280 8699 0 None - 1 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2280 8699 0 None - 1 Rat 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
53230038 8699 0 None - 1 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
53230038 8699 0 None - 1 Rat 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2271 9670 0 None - 0 Rat 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
1152 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
1152 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16129679 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
16129679 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
16132300 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
16132300 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
53395115 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
53395115 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
91898389 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
91898389 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
CHEMBL1981592 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
CHEMBL1981592 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
nan 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10570056
nan 10767 16 None -5 4 Human 8.5 pIC50 = 8.5 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9928018
2272 9852 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11068102
2271 9670 0 None - 0 Human 9.0 pIC50 = 9 Binding
inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9726637
3842 9214 0 None - 0 Human 4.5 pIC50 > 4.5 Binding
Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor
Guide to Pharmacology None None None None 9437714
3842 9214 0 None - 0 Human 6.0 pIC50 > 6 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11931347
129887154 7370 0 None - 1 Human 9.2 pKd = 9.2 Binding
binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
155817438 7370 0 None - 1 Human 9.2 pKd = 9.2 Binding
binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
16214732 7370 0 None - 1 Human 9.2 pKd = 9.2 Binding
binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
2269 7370 0 None - 1 Human 9.2 pKd = 9.2 Binding
binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
2281 7370 0 None - 1 Human 9.2 pKd = 9.2 Binding
binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 11978642
53314964 223100 0 125I-VIP -1 3 Rat 9.4 pKi = 9.4 Binding
NoneNone
PDSP KiDatabase 3325 113 51 48 -14.6 CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N None
53314964 223100 0 125I-VIP -5 3 Human 8.7 pKi = 8.7 Binding
NoneNone
PDSP KiDatabase 3325 113 51 48 -14.6 CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N None
53314964 223100 0 125I-VIP -1 3 Rat 8.7 pKi = 8.7 Binding
NoneNone
PDSP KiDatabase 3325 113 51 48 -14.6 CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N None
53314964 223100 0 125I-VIP -5 3 Human 8.3 pKi = 8.3 Binding
NoneNone
PDSP KiDatabase 3325 113 51 48 -14.6 CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N None
53314964 223100 0 125I-VIP -5 3 Human 8.2 pKi = 8.2 Binding
NoneNone
PDSP KiDatabase 3325 113 51 48 -14.6 CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N None
1152 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
16129679 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
16132300 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
53395115 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
91898389 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
CHEMBL1981592 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
nan 10767 16 None -5 4 Human 7.8 pKi = 7.8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
2276 10118 0 None 316 2 Human 8.0 pKi = 8 Binding
inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 9152366
2278 7116 0 None -316 2 Human 5.6 pKi = 5.6 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
1152 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
16129679 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
16132300 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
53395115 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
91898389 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
CHEMBL1981592 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
nan 10767 16 None -5 4 Human 8.8 pKi = 8.8 Binding
inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor
Guide to Pharmacology None None None None 10801840
1152 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
16129679 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
16132300 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
53395115 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
91898389 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
CHEMBL1981592 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823
nan 10767 16 None -5 4 Human 8.7 pKi = 8.7 Binding
inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor
Guide to Pharmacology None None None None 9454823